Windtree Therapeutics Reports $10.6 Million Net Loss for Q2 2025, Plans Strategic Shift

Windtree Therapeutics, Inc. reported a net loss of $10.6 million for the three months ended June 30, 2025, a decrease from a net loss of $12.0 million during the same period in 2024. For the six months ended June 30, 2025, the company recorded a net loss of $14.7 million, compared to a significantly lower loss of $1.8 million in the prior year. The increase in losses is attributed to a substantial decline in research and development expenses, which fell to $2.2 million from $9.9 million year-over-year, primarily due to the absence of non-recurring costs associated with the acquisition of in-process research and development from Varian Biopharmaceuticals in 2024.

The company’s total operating expenses for the second quarter of 2025 were $3.98 million, down from $11.45 million in the same quarter of 2024. This reduction reflects a strategic shift in focus, as Windtree has decided to terminate its SEISMiC C clinical trial to concentrate on advancing istaroxime for acute heart failure, a decision influenced by limited resources. The company is also pursuing a new corporate strategy aimed at generating revenue through acquisitions of small companies and their FDA-approved products.

Windtree's financial position as of June 30, 2025, showed total assets of $31.8 million, an increase from $27.9 million at the end of 2024. However, the company reported current liabilities of $15.7 million, leading to concerns about its ability to continue operations beyond December 2025 without securing additional capital. The company had cash and cash equivalents of $0.3 million at the end of the reporting period, which raises substantial doubt about its ability to continue as a going concern.

In terms of operational developments, Windtree has initiated a new crypto treasury strategy, which includes a $60 million securities purchase agreement aimed at acquiring the native token of the BNB chain. This strategy is part of a broader effort to enhance liquidity and financial stability. Additionally, the company has entered into an equity line of credit agreement, allowing it to sell up to $35 million in common stock, which it plans to utilize for operational expenses and to support its development programs.

Looking ahead, Windtree anticipates continued operating losses as it seeks to advance its product candidates and secure additional funding. The company is actively exploring various financing options, including public and private securities offerings, convertible debt financings, and strategic partnerships. However, there is no assurance that it will be successful in obtaining the necessary capital to fund its operations and development activities.